Development of latent Interferon alpha 2b as a safe therapeutic for treatment of Hepatitis C virus infection

Interferon therapy for the treatment of hepatitis C virus infection has very limited clinical application due to short serum half-life and side effects of therapy in systemic route of administration. In the present study, we have focused to improve the interferon therapy by overcoming the limitation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gull, Iram, Aslam, Muhammad Shahbaz, Tipu, Imran, Mushtaq, Roohi, Ali, Tehseen Zamir, Athar, Muhammad Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659634/
https://www.ncbi.nlm.nih.gov/pubmed/31350425
http://dx.doi.org/10.1038/s41598-019-47074-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659634/
https://www.ncbi.nlm.nih.gov/pubmed/31350425
http://dx.doi.org/10.1038/s41598-019-47074-y

Ejemplares similares